Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Legend Biotech Corporation (DE:9LB)
MUNICH:9LB
Legend Biotech (9LB) Stock Price & Analysis
1 Followers
9LB Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€41.00 - €69.50
Previous Close€41.8
Volume0.00
Average Volume (3M)88.00
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$1.28B
Total Debt (Recent Filing)$383.94M
Price to Earnings (P/E)N/A
Beta0.40
Next Earnings
May 13, 2024EPS Estimate
-€0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume88
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
€80.71Price Target Upside93.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Legend Biotech News
PremiumCompany Announcements
European Approval for Legend Biotech’s Myeloma Treatment
PremiumCompany Announcements
Legend Biotech Reports Preliminary Sales SurgeBulls Say, Bears Say
Bulls Say
Market OpportunityApproval in the 2L setting significantly increases the market opportunity for CARVYKTI.
Production GoalsLegend and Janssen are on track to achieve 10,000 doses of capacity by year-end 2025, showcasing a strong commitment to meeting production goals.
Regulatory MilestoneCarvykti receives European Commission approval for the treatment of multiple myeloma, expanding its total addressable population.
Bears Say
Manufacturing Capacity ConstraintsKey risk: lower-than-expected Carvykti sales due to manufacturing capacity constraint.
Regulatory And Safety ConcernsThe updated label for CARVYKTI includes a warning for increased early mortality risk compared to the control arm.
Sales PerformanceCarvykti Q1 revenue was flat at $157M, missing consensus estimates by 6.5%.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.00% Mutual Funds
0.56% Other Institutional Investors
99.44% Public Companies and
Individual Investors
9LB FAQ
What was Legend Biotech Corporation’s price range in the past 12 months?
Legend Biotech Corporation lowest stock price was €41.00 and its highest was €69.50 in the past 12 months.
What is Legend Biotech Corporation’s market cap?
Currently, no data Available
When is Legend Biotech Corporation’s upcoming earnings report date?
Legend Biotech Corporation’s upcoming earnings report date is May 13, 2024 which is in 15 days.
How were Legend Biotech Corporation’s earnings last quarter?
Legend Biotech Corporation released its earnings results on Mar 11, 2024. The company reported -€0.374 earnings per share for the quarter, missing the consensus estimate of -€0.332 by -€0.041.
Is Legend Biotech Corporation overvalued?
According to Wall Street analysts Legend Biotech Corporation’s price is currently Undervalued.
Does Legend Biotech Corporation pay dividends?
Legend Biotech Corporation does not currently pay dividends.
What is Legend Biotech Corporation’s EPS estimate?
Legend Biotech Corporation’s EPS estimate is -€0.18.
How many shares outstanding does Legend Biotech Corporation have?
Currently, no data Available
What happened to Legend Biotech Corporation’s price movement after its last earnings report?
Legend Biotech Corporation reported an EPS of -€0.374 in its last earnings report, missing expectations of -€0.332. Following the earnings report the stock price went up 4.386%.
Which hedge fund is a major shareholder of Legend Biotech Corporation?
Among the largest hedge funds holding Legend Biotech Corporation’s share is RA Capital Management. It holds Legend Biotech Corporation’s shares valued at 377M.
---
Legend Biotech Stock Smart Score
Company Description
Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Its other pipeline products include LB1910, LB1909, LB1903, and others. Geographically, the company generates a majority of its revenue from North America.
---
9LB Earnings Call
Q4 2024
0:00 / 0:00
---
9LB Stock 12 Months Forecast
Average Price Target
€80.71
▲(93.09% Upside)
Technical Analysis
Best Analysts Covering 9LB
1 Year
1 Year Success Rate
6/10 ratings generated profit
1 Year Average Return
-2.16%
reiterated a buy rating 12 days ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of -2.16% per trade.
---